(VIANEWS) – The Market ended the session with BERGENBIO (BGBIO.OL) jumping 10.47% to kr1.90 on Wednesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI slid 0.47% to kr1,210.96, following the last session’s downward trend on what was a somewhat down trend exchanging session today.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase II clinical development that focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and COVID-1. The company is also developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase Ib clinical trial. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-3.76.
Volatility
BERGENBIO’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.84%, a negative 1.00%, and a positive 3.49%.
BERGENBIO’s highest amplitude of average volatility was 7.30% (last week), 5.01% (last month), and 3.49% (last quarter).
More news about BERGENBIO (BGBIO.OL).
